Methylphenidate Viatris

Methylphenidate, the active ingredient in Methylphenidate Viatris, is a central nervous system stimulant presented as an oral tablet for oral use. It is indicated for the management of attention deficit hyperactivity disorder (ADHD) and narcolepsy in children, adolescents, and adults.

GNH USA supplies Methylphenidate Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methylphenidate is a psychostimulant that acts on neurobehavioral pathways associated with attention and wakefulness. - Attention deficit hyperactivity disorder (ADHD): improves concentration, reduces hyperactivity and impulsivity. - Narcolepsy: decreases daytime sleepiness and improves wakefulness. - Off‑label academic performance support: may enhance focus in certain clinical contexts under specialist supervision.

Methylphenidate may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Appetite loss: reduced hunger leading to weight loss. - Headache: mild to moderate intensity. - Stomach upset: nausea or abdominal discomfort. - Increased heart rate: mild tachycardia. - Irritability: mood changes or agitation.

Serious or Rare Side Effects: - Cardiovascular events: hypertension, arrhythmia, or chest pain. - Psychiatric symptoms: new or worsening psychosis, mania, or severe anxiety. - Growth suppression: reduced height or weight gain in children. - Seizures: rare occurrence of convulsive episodes. - Allergic reactions: rash, swelling, or anaphylaxis.

Methylphenidate requires careful assessment before and during therapy. - Cardiovascular assessment: evaluate blood pressure and heart rate prior to initiation. - Psychiatric history: screen for mood disorders, psychosis, or substance abuse. - Growth monitoring: regularly track height and weight in pediatric patients. - Drug dependence: assess risk of misuse or diversion. - Storage: Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Methylphenidate can interact with several medication classes, affecting safety or efficacy.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Tricyclic antidepressants: may increase cardiovascular side effects. - Antihypertensives: potential reduction in blood pressure control.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may alter absorption. - Anticonvulsants: possible reduction in seizure threshold. - Alcohol: can exacerbate central nervous system stimulation.